BCMA-targeted strategies have significantly advanced MM treatment, especially with the success of ADCs, bispecific T-cell engagers (BiTEs), and CAR-T cell therapies [118,119,120]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.